PerkinElmer Finalizes Acquisition of SimoTech to Bolster Biopharma Automation Capabilities
PerkinElmer, Inc. has officially completed its acquisition of SimoTech, a strategic move designed to significantly enhance the company’s end-to-end Good Manufacturing Practice (GMP) automation and digital manufacturing infrastructure. The deal, which follows an initial agreement reached this past August, marks a major milestone in PerkinElmer’s ongoing effort to provide comprehensive, high-tech solutions for the global biopharmaceutical sector.
By integrating SimoTech’s specialized expertise, PerkinElmer aims to provide its customers with a more robust platform to accelerate the development and commercial production of life-saving medical treatments.
Strengthening the Pharmaceutical Services Ecosystem
Founded in 2011 and based in Cork, Ireland, SimoTech has established itself as a critical player in the biopharmaceutical landscape. The firm currently provides support to half of the world’s top 20 pharmaceutical and biotechnology organizations. SimoTech specializes in developing and implementing automation and digital manufacturing systems that help companies streamline project execution, enhance operational performance, and maintain rigorous regulatory compliance.
The acquisition of this PerkinElmer completes SimoTech acquisition is set to create a powerful synergy within the organization. By combining SimoTech’s GMP IT and automation proficiency with PerkinElmer’s existing OneSource integrated laboratory services and the manufacturing engineering capabilities of Project Farma, the company is creating a highly differentiated, scalable platform for pharmaceutical clients.
Strategic Vision for the Future
“By combining SimoTech’s expertise in manufacturing automation and digital systems with the capabilities of OneSource and Project Farma, this acquisition creates a significant opportunity to build a differentiated, scaled platform for pharmaceutical services,” said Michael Stubblefield, CEO of PerkinElmer. “We are excited to welcome SimoTech’s exceptional team to the PerkinElmer family.”
For clients in the drug development space, the integration promises a more seamless transition from laboratory research to large-scale manufacturing. Anshul Mangal, President of PerkinElmer’s Pharma Specialty Services business, emphasized the importance of this integration:
“The combination of OneSource, Project Farma, and SimoTech creates a unique opportunity to strengthen our partnerships with leading innovators and reduce the time to market for life-changing therapies,” said Mangal. “SimoTech’s expertise in automation and IT systems is a natural complement to our capabilities, enabling us to support customers across the full drug development and manufacturing lifecycle.”
As the biopharmaceutical industry continues to move toward more digitized and automated workflows, this acquisition positions PerkinElmer to play a central role in the industry’s evolution. By offering an integrated suite of services, the company intends to unlock new growth opportunities while helping manufacturers navigate the complexities of modern drug production.
For more insights into the shifting landscape of the life sciences sector, readers can explore the Pharmaceutical Industry Mergers & Acquisitions Roundup on Contract Pharma.
